ABSTRACT
There is increasing recognition of the risk of developing therapy-related myeloid malignancy, including after cellular therapy. While retrospective studies have implicated pre-existing TP53 mutated hematopoietic clones as a common causative mechanism, no prospective screening to identify those patients at greatest risk is currently possible. We demonstrate that ultradeep DNA-sequencing prior to therapy may be used for discovery of TP53 mutations that are subsequently associated with malignancy.
Competing Interest Statement
Research at the Laboratory of Myeloid Malignancies, NHLBI is supported by the Foundation of the NIH AML MRD Biomarkers Consortium. The authors declare no other competing interests.
Funding Statement
This work was funded by the Intramural Research Program of the National Heart, Lung, and Blood Institute of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
A part of the current study includes human data that were originally published as: Ghannam, J.Y., Xu, X., Maric, I., Dillon, L., Li, Y., Hsieh, M.M., Hourigan, C.S. and Fitzhugh, C.D., 2020. Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation. Blood, The Journal of the American Society of Hematology, 135(14), pp.1185-1188. https://ashpublications.org/blood/article/135/14/1185/452511/Baseline-TP53-mutations-in-adults-with-SCD
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing interests: Research at the Laboratory of Myeloid Malignancies, NHLBI is supported by the Foundation of the NIH AML MRD Biomarkers Consortium. The authors declare no other competing interests.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
